Vodafone Idea Limited FPO...
26 Aug, 2025
Anthem Biosciences Limited IPO
Anthem Biosciences Limited is one of India’s top innovation-driven Contract Research, Development and Manufacturing Organizations (CRDMO) set to launch its IPO. The issue size is ₹3,395.00 crores. Anthem Biosciences IPO offer consists entirely of 5.96 crore shares being sold by existing shareholders. The IPO price band is set for ₹540 to ₹570 per share, with a face value of ₹2 per share. It opens for subscription on July 14, 2025 and closes on July 16, 2025. A minimum of 26 shares per application is applicable.
Company Background
Anthem Biosciences Limited was established in 2006 and is in the business of innovation and technology in the CRDMO sector, with fully integrated operations in drug discovery, development and manufacturing. The company is a services provider to new biotech firms and large pharmaceutical companies worldwide, across more than 44 countries, including the U.S., Europe and Japan.
Anthem Biosciences is engaged in the production of fermentation-based APIs, probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Up to September 2024, the company was implementing 196 projects. Out of them, 170 projects were in the discovery phase and 13 projects were in commercial manufacturing. It is supported by a strong intellectual property (IP) portfolio, which consists of an Indian patent, seven overseas patents and 24 pending global patent applications.
Operations and Product Range
Facility and Production
Anthem Biosciences runs advanced research and manufacturing facilities that support the entire process from drug lifecycle, from discovery to commercial production. Its infrastructure allows it to offer complete solutions for both small molecules and biologics.
Brand and Market Presence
Anthem Biosciences has a strong foothold as a reliable partner for pharmaceutical and biotech companies worldwide, providing services and products across the U.S., Europe, Japan and other key markets. Its influence in the market is based on its innovation, quality and focus on customer needs.
Revenue Channels
Anthem Biosciences Limited makes money mainly through:
Contract Research and Development: Offering discovery and early-phase research services for global clients.
Commercial Manufacturing: Producing APIs and intermediates for commercial supply.
Specialty Ingredients: Supplying fermentation-based products, enzymes, peptides and nutritional actives.
Long-Term Partnerships: Creating recurring revenue with long-term clients in the pharmaceutical and biotech sectors.
Management & Shareholding
Promoters & Shareholding
The promoters of Anthem Biosciences Limited are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj. Before the IPO, the promoters collectively owned 76.87% of the equity, which is expected to decrease to 74.68% after the issue.
Board Members
The board includes Managing Director Kunal Bhimji Patel and Full-time Director and Chairman Bhimji Nanji Patel. Independent directors Prasannakumar Baliram Gawde, Nayan Jagdishchandra Rawal and Jagruti Prashant Sheth also serve on the board.
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Anthem Biosciences Limited IPO
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| - | - | - | - |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Anthem Biosciences Limited IPO Details
| Detail | Description |
|---|---|
| IPO Date | July 14, 2025 to July 16, 2025 |
| Listing Date | July 21, 2025 (Tentative) |
| Face Value | ₹2 per share |
| Issue Price Band | ₹540 to ₹570 per share |
| Lot Size | 26 Shares |
| Sale Type | Offer for Sale |
| Total Issue Size | 5,95,61,404 shares (₹3,395.00 Cr) |
| Employee Discount | ₹50 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Shareholding Pre-Issue | 55,90,77,100 shares |
| Shareholding Post Issue | 55,90,77,100 shares |
Anthem Biosciences Limited IPO Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Mon, Jul 14, 2025 |
| IPO Close Date | Wed, Jul 16, 2025 |
| Tentative Allotment | Thu, Jul 17, 2025 |
| Initiation of Refunds | Fri, Jul 18, 2025 |
| Credit of Shares to Demat | Fri, Jul 18, 2025 |
| Tentative Listing Date | Mon, Jul 21, 2025 |
| Cut-off time for UPI mandate | 5 PM on July 16, 2025 |
Anthem Biosciences Limited IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,820 |
| Retail (Max) | 13 | 338 | ₹1,92,660 |
| S-HNI (Min) | 14 | 364 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,742 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,768 | ₹10,07,760 |
Anthem Biosciences Limited IPO Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 76.87% | 74.68% |
Competitive Strength:
- One-stop Service: Integrated solutions across the drug lifecycle for small molecules and biologics.
- Innovation-driven: With a strong focus on research and development and modern manufacturing technologies.
- Specialized Model: Customized solutions for small pharma and biotech companies.
- Diverse & Loyal Client Base: Long-term relationships with over 550 clients worldwide.
- Experienced Leadership: Skilled management and a well-qualified scientific team.
Anthem Biosciences Limited IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Total Borrowing | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 2,807.58 | 1,930.29 | 451.26 | 2,409.86 | 108.95 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 2,398.11 | 1,483.07 | 367.31 | 1,924.66 | 232.53 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 2,014.46 | 1,133.99 | 385.19 | 1,740.67 | 125.06 | |||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 20.82% |
| ROCE | 26.88% |
| Debt/Equity | 0.05 |
| RoNW | 20.82% |
| PAT Margin | 23.38% |
| EBITDA Margin | 36.81% |
| Price to Book Value | 13.23 |
| Pre IPO EPS (₹) | 8.07 |
| Post IPO EPS (₹) | 8.07 |
| Pre IPO P/E (x) | 70.62 |
| Post IPO P/E (x) | 70.62 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | ||
| P/E (x) |
The Objective of Anthem Biosciences IPO
The Anthem Biosciences IPO is an Offer for Sale (OFS). The company will not receive any money from the IPO. All proceeds after deducting offer-related expenses and relevant taxes will go to the selling shareholders.
Conclusion
Anthem Biosciences IPO gives investors a chance to be part of one of India’s most innovative and fastest-growing CRDMOs. The company has a fully integrated service model and focuses heavily on research and technology. It also has a diverse and loyal customer base as well as a skilled management team. Anthem Biosciences has shown strong financial growth and works in a high-margin, high-growth area of the pharmaceutical industry.
However, investors should keep in mind that since the IPO is entirely an offer for sale, the company will not receive any new capital from this issue. The IPO is best for investors looking to gain exposure to a global leader in contract drug research and manufacturing, with a solid track record of innovation and customer relationships.
RHP:
DRHP:
Read more :
Frequently asked Questions (FAQs )
-
1. What is the Anthem Biosciences IPO?
Anthem Biosciences IPO is a main-board IPO of 5,95,61,404 equity shares of the face value of ₹2, aggregating up to ₹3,395.00 Crores.
-
2. What is the opening date for the Anthem Biosciences IPO?
The Anthem Biosciences IPO opens on July 14, 2025 and closes on July 16, 2025.
-
3. What is the minimum lot size for the Anthem Biosciences IPO?
Anthem Biosciences IPO lot size is 26 and the minimum amount required for application is ₹14,820.
-
4. What is the listing date for the Anthem Biosciences IPO?
The Anthem Biosciences IPO listing date has not yet been announced. The tentative date of Anthem Biosciences' IPO listing is Monday, July 21, 2025.
-
5. When is the Allotment for the Anthem Biosciences IPO?
The finalization of the Basis of Allotment for Anthem Biosciences IPO will be done on Thursday, July 17, 2025 and the allotted shares will be credited to the buyer’s demat account by Friday, July 18, 2025.
.jpg)
